Product Code: SR1020A08_Report
The global autoimmune disease diagnosis market reached a value of US$ 4.4 Billion in 2020. An autoimmune disease refers to a condition wherein the immune system attacks and destroys healthy cells, tissues, and organs of the body. In the longer run, it can also lead to abnormal growth of an organ and changes in organ function. Currently, more than 80 different autoimmune disorders have been identified by scientists, out of which Systemic Lupus Erythematosus (SLE), multiple sclerosis, rheumatoid arthritis, and type I diabetes, are the most common. Depending on the disorder, the doctor uses a combination of methods, which include a physical examination, medical history, blood tests, biopsy, and X-rays, to provide an effective diagnosis. They prescribe anti-inflammatory and immunosuppressant drugs, physical therapy, surgery, and injections, to control the overactive immune response and provide relief from symptoms.
Owing to the rising prevalence of autoimmune diseases, healthcare professionals around the world are focusing on the adoption of advanced technologies to conduct multiple tests with faster and more precise results. Apart from this, a large number of research and diagnostics institutes are undertaking public awareness campaigns to educate individuals about autoimmune diseases and their possible treatments and diagnosis, which is positively influencing the market growth. Furthermore, several governing authorities, along with non-governing organizations, are funding various programs to develop novel therapeutics. For instance, the AMP RA/SLE Program, launched by the Accelerating Medicines Partnership (AMP), is a public-private partnership between the National Institutes of Health (NIH), the US Food and Drug Administration (FDA) and multiple non-profit organizations. The program aims to identify relevant drug targets for the treatment of autoimmune diseases. Looking forward, IMARC Group expects the global autoimmune disease diagnosis market to grow at a CAGR of 8.10% during 2021-2026.
Breakup by Product Type:
- Consumables and Assay Kits
- Instruments
Breakup by Disease Type:
- Systemic Autoimmune Disease
- Rheumatoid Arthritis
- Psoriasis
- Systemic Lupus Erythematosus (SLE)
- Multiple Sclerosis
- Others
- Localized Autoimmune Disease
- Inflammatory Bowel Disease
- Type 1 Diabetes
- Thyroid
- Others
Breakup by Test Type:
- Routine Laboratory Tests
- Inflammatory Markers
- Autoantibodies and Immunologic Tests
- Others
Breakup by End-User:
- Clinical Laboratories
- Hospitals
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
- The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Aesku.Diagnostics GmbH & Co. KG, Beckman Coulter Inc. (Danaher Corporation), bioMerieux SA (Institut Merieux), Bio-Rad Laboratories Inc., Euroimmun AG (PerkinElmer Inc.), Hemagen Diagnostics Inc., Inova Diagnostics Inc. (Werfen Group S.A.), Myriad Genetics Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG (Siemens AG), SQI Diagnostics, Thermo Fisher Scientific Inc., Trinity Biotech, etc.
Key Questions Answered in This Report:
- How has the global autoimmune disease diagnosis market performed so far and how will it perform in the coming years?
- What are the key regional markets?
- What has been the impact of COVID-19 on the global autoimmune disease diagnosis market?
- What is the breakup of the market based on the product type?
- What is the breakup of the market based on the disease type?
- What is the breakup of the market based on the test type?
- What is the breakup of the market based on the end-user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global autoimmune disease diagnosis market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Autoimmune Disease Diagnosis Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Consumables and Assay Kits
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Instruments
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Disease Type
- 7.1 Systemic Autoimmune Disease
- 7.1.1 Market Trends
- 7.1.2 Market Breakup by Type
- 7.1.2.1 Rheumatoid Arthritis
- 7.1.2.2 Psoriasis
- 7.1.2.3 Systemic Lupus Erythematosus (SLE)
- 7.1.2.4 Multiple Sclerosis
- 7.1.2.5 Others
- 7.1.3 Market Forecast
- 7.2 Localized Autoimmune Disease
- 7.2.1 Market Trends
- 7.2.2 Market Breakup by Type
- 7.2.2.1 Inflammatory Bowel Disease
- 7.2.2.2 Type 1 Diabetes
- 7.2.2.3 Thyroid
- 7.2.2.4 Others
- 7.2.3 Market Forecast
8 Market Breakup by Test Type
- 8.1 Routine Laboratory Tests
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Inflammatory Markers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Autoantibodies and Immunologic Tests
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by End-User
- 9.1 Clinical Laboratories
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Hospitals
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Aesku.Diagnostics GmbH & Co. KG
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 Beckman Coulter Inc. (Danaher Corporation)
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 SWOT Analysis
- 14.3.4 bioMerieux SA (Institut Merieux)
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Bio-Rad Laboratories Inc.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Euroimmun AG (PerkinElmer Inc.)
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.7 Hemagen Diagnostics Inc.
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Inova Diagnostics Inc. (Werfen Group S.A.)
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.9 Myriad Genetics Inc.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Quest Diagnostics Incorporated
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Siemens Healthineers AG (Siemens AG)
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.12 SQI Diagnostics
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.12.3 Financials
- 14.3.13 Thermo Fisher Scientific Inc.
- 14.3.13.1 Company Overview
- 14.3.13.2 Product Portfolio
- 14.3.13.3 Financials
- 14.3.13.4 SWOT Analysis
- 14.3.14 Trinity Biotech
- 14.3.14.1 Company Overview
- 14.3.14.2 Product Portfolio
- 14.3.14.3 Financials
- 14.3.14.4 SWOT Analysis
比較リスト
